Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

SWOG / S2302

Trial Overview

Official Title

Non-chemotherapy treatment (Ramucirumab plus Pembrolizumab) or usual care for advanced non-small cell lung cancer following immunotherapy

Study Purpose

To compare overall survival in participants previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer randomized to Pembrolizumab and Ramucirumab versus standard of care.

 

Diagnosis

Stage IV disease or recurrent non-small cell lung cancer

Eligibility

Biopsy proven disease, received one Anti-PDL-1 therapy previously, must have experienced disease progression within certain time frames

 

Intervention

Arm A

Standard of Care

 

Arm B

Ramucirumab + Pembrolizumab

 

 

For more information, go to the link below:

 

https://clinicaltrials.gov/study/NCT05633602?term=S2302&rank=1

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center Methodist Jennie Edmundson Hospital
Gender
Male or Female
Age
19 years old and over
Enrollment Status
Recruiting
Phase
Phase IV
Methodist Health System Trial Code
S2302